Vertex Energy (VTNR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...
Vertex Pharmaceuticals Incorporated data readout from a phase 3 program, using VX-548 for the treatment of patients with acute pain, could be released by the 1st half of 2024. Proof of concept, using ...
Vertex Pharmaceuticals (NASDAQ: VRTX) is trading near a record high after climbing about 20% so far this year, and delivering a triple-digit gain over three years. So, you may be a bit hesitant about ...
Vertex (NASDAQ:VRTX) is a $76bn market cap, commercial stage pharmaceutical company based in the biotech heartland of Boston, Massachusetts. The company's success in growing revenues from $580m in ...
Shares of Vertex Pharmaceuticals soared in 2022 while the major stock market indexes tumbled. Vertex Pharmaceuticals markets the only drugs approved to treat cystic fibrosis, a progressive inherited ...
Vertex Pharmaceuticals has built a billion-dollar cystic fibrosis business over time. But the company today may be preparing for a new era of growth, thanks to the strength of its pipeline. Vertex ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback